The FDA, preemption, and the Supreme Court.
作者信息
Glantz Leonard H, Annas George J
机构信息
Department of Health Law, Bioethics, and Human Rights at Boston University School of Public Health, Boston, USA.
出版信息
N Engl J Med. 2008 May 1;358(18):1883-5. doi: 10.1056/NEJMp0802108.
PMID:18450601
Abstract
摘要
相似文献
1
The FDA, preemption, and the Supreme Court.
N Engl J Med. 2008 May 1;358(18):1883-5. doi: 10.1056/NEJMp0802108.
2
Why doctors should worry about preemption.
N Engl J Med. 2008 Jul 3;359(1):1-3. doi: 10.1056/NEJMp0804448.
3
Good law from tragic facts--Congress, the FDA, and preemption.
N Engl J Med. 2009 Sep 17;361(12):1206-11. doi: 10.1056/NEJMhle0902889.
4
A pivotal medical-device case.
N Engl J Med. 2008 Apr 17;358(16):1758. doi: 10.1056/NEJMc080148.
5
A pivotal medical-device case.
N Engl J Med. 2008 Apr 17;358(16):1758.
6
The need for federal preemption of state tort claims in the context of "new drugs" and premarket-approved medical devices.
Seton Hall Law Rev. 2011;41(2):723-63.
7
A pivotal medical-device case.
N Engl J Med. 2008 Jan 3;358(1):76-7. doi: 10.1056/NEJMe0708590.
8
Losing deference in the FDA's second century: judicial review, politics, and a diminished legacy of expertise.
Cornell Law Rev. 2008 Jul;93(5):939-80.
9
The FDA and deference lost: a self-inflicted wound or the product of a wounded agency? A response to Professor O'Reilly.
Cornell Law Rev. 2008 Jul;93(5):981-1002.
10
A pivotal medical-device case.
N Engl J Med. 2008 Apr 17;358(16):1758.
Zotero 插件